Prognostic value of serum aldo-keto reductase family 1 member B10 in hepatocellular carcinoma

Table 2 Cox regression analysis of the influencing factors on the survival time of hepatocellular carcinoma patients

Factors	Univariate analysis		Multivariate analysis
	HR (95%CI)	P value	HR (95%CI)	P value
Gender	1.103 (0.623-1.954)	0.736
Age	0.927 (0.577-1.489)	0.754
Smoking	1.349 (0.832-2.185)	0.224
Alcohol consumption	1.298 (0.807-2.087)	0.283
Viral hepatitis	1.203 (0.293-4.940)	0.797
Hepatic cirrhosis	0.793 (0.423-1.484)	0.468
Antiviral therapy	0.958 (0.612-1.586)	0.951
Number of tumors	1.261 (0.787-2.019)	0.336
Tumor size	1.617 (1.009-2.590)	0.046	1.346 (0.826-2.192)	0.233
Portal vein tumor thrombus	1.261 (0.761-2.091)	0.368
Vascular tumor thrombus	2.120 (0.767-5.856)	0.147
Metastasis to lymph nodes or distant metastasis	1.439 (0.755-2.743)	0.269
Ascites	2.249 (1.269-3.985)	0.006	1.810 (1.017-3.223)	0.044
Combined type 2 diabetes mellitus	1.139 (0.521-2.490)	0.744
Microvascular invasion	2.545 (1.076-6.024)	0.034	2.291 (0.963-5.452)	0.061
Satellite lesions	2.270 (0.547-9.429)	0.259
BCLC staging (AB/CD)	1.414 (0.879-2.273)	0.153
BMI index (≥ 25)	0.835 (0.492-1.415)	0.502
AFP (≥ 5.89 ng/mL)	1.518 (0.920-2.504)	0.102
AFP (≥ 20 ng/mL)	1.354 (0.845-2.170)	0.208
AFP (≥ 400 ng/mL)	1.728 (1.402-2.867)	0.034	1.469 (0.873-2.473)	0.148
GLU (≥ 6.1 mmol/L)	0.961 (0.549-1.683)	0.89
PT (≥ 13 seconds)	1.069 (0.654-1.747)	0.791
ALT (≥ 40 U/L)	1.343 (0.809-2.227)	0.254
AST (≥ 35 U/L)	1.335 (0.830-2.146)	0.234
TBIL (≥ 21 μmol/L)	1.182 (0.727-1.921)	0.5
ALB (≥ 55 g/L)	1.481 (0.919-2.388)	0.107
AKR1B10 (1584.97 pg/mL)	2.021 (1.137-3.593)	0.017	1.819 (1.009-3.280)	0.047

BCLC: Barcelona Clinic Liver Cancer; BMI: Body mass index; AFP: Alpha-fetoprotein; GLU: Glucose; PT: Prothrombin time; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; TBIL: Total bilirubin; ALB: Albumin; AKR1B10: Aldo-keto reductase family 1 member B10; HR: Hazard ratio; CI: Confidence interval.